Arbutus Biopharma Files 8-K

Ticker: ABUS · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, financials, operations

TL;DR

Arbutus Biopharma dropped an 8-K on Nov 6th, check financials and operations.

AI Summary

Arbutus Biopharma Corporation filed an 8-K on November 6, 2024, reporting on its results of operations, financial condition, and other events. The filing includes financial statements and exhibits. The company was formerly known as Tekmira Pharmaceuticals Corp.

Why It Matters

This 8-K filing provides an update on Arbutus Biopharma's operational and financial status, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting operational and financial information, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial results are detailed in this 8-K filing?

The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of the financial results are not provided in the excerpt.

What other events are reported in this 8-K?

The filing states it covers 'Other Events' in addition to results of operations and financial condition.

When was Arbutus Biopharma Corporation previously known by another name?

The company was formerly known as Tekmira Pharmaceuticals Corp, with name changes noted on June 7, 2011, and October 3, 2008.

Where is Arbutus Biopharma Corporation's principal executive office located?

The principal executive office is located at 701 Veterans Circle, Warminster, Pennsylvania, 18974.

What is the Standard Industrial Classification code for Arbutus Biopharma Corporation?

The Standard Industrial Classification code for Arbutus Biopharma Corporation is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001171843-24-006039.txt : 20241106 0001171843-24-006039.hdr.sgml : 20241106 20241106073141 ACCESSION NUMBER: 0001171843-24-006039 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 40 CONFORMED PERIOD OF REPORT: 20241106 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241106 DATE AS OF CHANGE: 20241106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241429247 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 f8k_110624.htm FORM 8-K Form 8-K 0001447028 False 0001447028 2024-11-06 2024-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 8-K _________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  November 6, 2024 _______________________________ Arbutus Biopharma Corporation (Exact name of registrant as specified in its charter) _______________________________ British Columbia, Canada 001-34949 98-0597776 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 701 Veterans Circle Warminster , Pennsylvania 18974 (Address of Principal Executive Offices) (Zip Code) ( 267 ) 469-0914 (Registrant's telephone number, including area code)   (Former name or former address, if changed since last report) _______________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, without par value ABUS The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐     Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2024 and certain other information. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated by reference herein. Item 8.01. Other Events. On November 6, 2024, the Company posted an updated corporate

View on Read The Filing